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Traditional Chinese Medicines are promising sources of new agents for controlling cancer
metastasis. Compound Kushen Injection (CKI), prepared from medicinal plants Sophora
flavescens and Heterosmilax chinensis, disrupts cell cycle and induces apoptosis in
breast cancer; however, effects on migration and invasion remained unknown. CKI,
fractionated mixtures, and isolated components were tested in migration assays with
colon (HT-29, SW-480, DLD-1), brain (U87-MG, U251-MG), and breast (MDA-MB-231)
cancer cell lines. Human embryonic kidney (HEK-293) and human foreskin fibroblast
(HFF) served as non-cancerous controls. Wound closure, transwell invasion, and live cell
imaging showed CKI reduced motility in all eight lines. Fractionation and reconstitution
of CKI demonstrated combinations of compounds were required for activity. Live cell
imaging confirmed CKI strongly reduced migration of HT-29 and MDA-MB-231 cells,
moderately slowed brain cancer cells, and had a small effect on HEK-293. CKI uniformly
blocked invasiveness through extracellular matrix. Apoptosis was increased by CKI in
breast cancer but not in non-cancerous lines. Cell viability was unaffected by CKI in all
cell lines. Transcriptomic analyses of MDA-MB-231indicated down-regulation of actin
cytoskeletal and focal adhesion genes with CKI treatment, consistent with observed
impairment of cell migration. The pharmacological complexity of CKI is important for
effective blockade of cancer migration and invasion.
Keywords: traditional chinese medicine (TCM), compound kushen injection (CKI), cell migration, invasion, cancer,
gene regulatory networks, alternative medicine
INTRODUCTION
Cancer progression results from uncontrolled migration of cells away from the primary tumor,
intravasation into lymphatic or vascular circulation, invasion into secondary tissues and the
formation of metastasized tumors (1, 2) which are the main cause of cancer-related deaths (3–5).
Migrating cells generate a driving force for cell motility based on the extension of filipodia and
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lamellipodia using actin polymerization at the leading edges of
the cell (6). New approaches for enhancing cancer treatment by
impairing cell migration and metastasis might offer promise for
curing patients with malignancies. Combinations of anticancer
therapeutic regimens that not only reduce cell proliferation but
also limit metastasis would be advantageous (7–9).
Herbal medicines are used in complementary and traditional
medicines (10–12). Traditional Chinese medicine (TCM) relies
on natural product extracts containing complex mixtures
of components, suggested to deliver therapeutic benefit to
individuals suffering from non-small cell lung cancer, liver,
breast, and colorectal cancers (10, 13, 14). The inherent
complexity of TCM suggests principle components might act
in concert with adjuvant components, explaining an apparent
synergy in therapeutic benefits seen from the whole extract as
compared to individual compounds (15). Modulation of multiple
regulatory signaling targets has been proposed as essential for the
anti-proliferative, anti-migratory and anti-metastatic properties
of TCMs (16, 17).
Compound Kushen Injection (CKI) has been used in
combination with chemotherapies such as oxaliplatin and 5-
fluorouracil in China since 1995 for the treatment of gastric,
liver and non-small cell lung carcinomas (18). Composed of
alkaloids, flavonoids, organic acids and saccharides (19), CKI
has been reported to boost immunity, decrease inflammation,
and decrease metastasis (20), for example by repressing RNA
markers associated with tumormetastasis inMCF-7 cells (17, 18),
and impairing migration in hepatocellular carcinoma cells (21).
The challenge for defining mechanisms of action of TCMs such
as CKI is to understand the differential activities of chemical
components not only singly but in combination, recognizing
the likely involvement of multiple gene expression and signaling
pathways in the beneficial outcomes (22).
Work here is the first to show that CKI and defined chemical
fractions slow cancer cell migration and invasion, and to use
systems biology to identify sets of genes linked to cell migration
that are regulated by CKI treatment. Differential expression of
genes in the actin cytoskeleton and focal adhesion pathways
supports the idea that the therapeutic activity of CKI in humans




MDA-MB-231, HT-29, SW-480, DLD-1, U-87 MG, U-251MG,
and HEK-293 were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and human foreskin fibroblast
(HFF) was kindly provided by Dr. Eric Smith (Basil Hetzel
Institute, The Queen Elizabeth Hospital, SA, Australia). DLD-
1 cells were grown in RPMI (Roswell Park Memorial Institute)
culture medium (Thermo Fisher Scientific, MA, USA) with 10
% fetal bovine serum (FBS, Thermo Fisher Scientific). All other
cell lines were cultured in Dulbecco Modified Eagle Medium
(DMEM, Thermo Fisher Scientific) with 10 % FBS, except for
HFF (which contained 15 % FBS), at 37◦C in 5 % CO2.
CKI Preparation and Other Chemicals
CKI (Batch No: 20170322, total alkaloid concentration of 25
mg/ml) was obtained from Zhendong Pharmaceutical Co. Ltd
(Shanxi, China). High performance liquid chromatography
(HPLC) fractionation and liquid chromatography-mass
spectrometry (LC-MS/MS) were used to analyse single
compounds and confirm their concentrations in CKI.
Fractionation of CKI was done by using Shimadzu HPLC
SPC-M20A photodiode-array UV-Vis detector (Japan)
equipped with a C18 column (5µm, 250 × 10mm;
Phenomenex, CA, USA), with methods for fractionation
and concentration determinations as described previously (23)
(Supplementary Images 2, 3). The nine compounds comprising
the major fraction (MJ): oxymatrine, oxysophocarpine, n-
methylcytisine, matrine, sophocarpine, trifolirhizin, adenine,
and sophoridine were purchased as isolated compounds from
Beina Biotechnology Institute Co., Ltd (Shanxi, China), and
macrozamin was obtained from Zhendong Pharmaceutical Co.
Ltd (Beijing, China). Two-fold serial dilutions from 2 mg/ml
through to 0.25 mg/ml of total alkaloids in CKI, as well as
equivalent dilutions of the MJ and minor (MN) fractions were
used for bioassay experiments on the cancer and non-cancerous
cell lines and compared with effects of vehicle control treatments;
0.25% Tween 80 (Sigma-Aldrich, MO, USA) and 10mM HEPES
(Thermo Fisher Scientific) in the same cell lines.
Circular Wound Closure Assay
Two-dimensional (2D) cell migration was measured using
circular wound closure rates (24). CKI-based and vehicle control
treatments were applied in low serum DMEM, with the mitotic
inhibitor 5-fluoro-2′-deoxyuridine (FUDR). Initial wound areas
were imaged at 0 h (10x objective) with a Canon EOS 6D camera
(Canon, Tokyo, Japan) on an Olympus inverted microscope
(Olympus Corp., Tokyo, Japan); XnConvert software was used
to standardize the images. NIH ImageJ software (U.S. National
Institutes of Health, MD, USA) was used to quantify wound areas
at 0 h and at a second timepoint (18–24 h), set for each cell line
to ensure wounds were not completely closed. Experiments were
independently repeated three times, with four to eight replicates.
Transwell Invasion Assay
Invasion assays were performed in 24-well transwell inserts
(6.5mm, 8µm pore size; Corning R© Transwell polycarbonate;
Sigma-Aldrich). The upper surface of the filter was layered with
extracellular matrix (ECM) gel from Sigma-Aldrich (at dilutions
empirically optimized for each cell line; Supplementary Table 2),
allowed to dry overnight, and rehydrated with 50 µl of serum-
free media per insert for 1 h prior to cell seeding. Cultures were
grown to 40% confluence and then starved in medium with 2%
FBS serum for 24 h prior to seeding. Cells were detached (at ≤
80% confluency) and resuspended in serum-free culture media
(Supplementary Table 2). Cells were then seeded in transwell
inserts (total 150 µl of cell suspension per transwell, including
50 µl of rehydration medium added earlier) at appropriate
number of cells per well in the presence of CKI, MN or MJ at 2
mg/ml, or vehicle control medium. The chemoattractant gradient
was created with 700 µl of culture medium (containing the
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relevant CKI-based or vehicle treatment), with 5, 10, or 15% FBS
for HEK-293, cancerous cells, or HFF, respectively. Depending on
invasion characteristics, cells from each line were incubated for
an optimized time period ranging from 5 to 24 h at 37◦C in 5%
CO2. Non-invasive cells were scraped from the upper surface of
the filter with a cotton swab; migrated cells on the bottom surface
were counted after staining with crystal violet (Sigma-Aldrich).
The average number of invasive cells was calculated from four
randomly selected fields (x100 magnification). Cell counts were
normalized to numbers in the vehicle control treatment. Three
independent experiments were carried out with two replicates.
Cytotoxicity Assay
Cell viability was measured with the Alamar Blue assay (25)
according to the manufacturer’s instructions (Thermo Fisher
Scientific). Cells were seeded in 96-well plates in media with
2% FBS and FUDR. After overnight incubation, treatments were
applied, and cultures were incubated for 24 h. After application
of 10% Alamar Blue solution (30–90min), fluorescence was
measured by using FLUOstar Optima microplate reader.
Mercuric chloride (2.5mM) served as a positive control, inducing
cytotoxic cell death. A control sample with medium and
treatment agent only (no cells) was included for background
color subtraction.
Apoptosis Assay
Apoptosis assays based on annexin V and propidium iodide
staining were performed as described previously (17). Briefly,
MDA-MB-231, HEK-293 and HFF cells were seeded in 6-
well trays and treated with 2 mg/ml of CKI. After 24 h of
treatment, cells were harvested, and levels of apoptotic cells
were measured using the Annexin V-FITC detection kit (Thermo
Fisher Scientific) according to the manufacturer’s guidelines.
Cells were acquired on a LSRFortessa X-20 (BD Biosciences, NJ,
USA) and data were analyzed using FlowJo software (TreeStar
Inc., OR, USA).
Live Cell Imaging
Cells in 96 well-plates were cultured to 80 % confluency, then
serum-starved for 12–18 h in optimal culture media with 2%
FBS and 400 nM FUDR. Wounds were created as circular lesions
in the confluent monolayers, and treatments were added as
described for the circular wound closure assay above. Plates
were placed in an enclosed humidified chamber at 37◦C with
5% CO2 for 20 h, and images were acquired at 10-min intervals
with a Nikon Ti E Live Cell Microscope (Nikon, Tokyo, Japan)
using Nikon NIS-Elements software. Time-lapse movies as AVI
files were exported from NIS-Elements. ImageJ (U.S. National
Institutes of Health) was used to convert the exported files into




Cells were plated in µ-Plate 8 Well dishes (Ibidi, Munich,
Germany), in 2 % FBS with FUDR 400 nM in optimal culture
media and incubated 12–18 h at 37◦C in 5% CO2. The following
day, 2 mg/ml of CKI, MN, MJ or vehicle control treatments
were applied, and cells were incubated for 24 h. After washing
with phosphate-buffered saline (PBS), cells were fixed in 4 %
paraformaldehyde (at room temperature for 10–30min), rinsed
2–3 times with PBS, and permeabilized with 200 µl of 0.1%
Triton X-100 in PBS (3–5min at room temperature). After 2–
3 washes with PBS, Phalloidin-iFluor 488 Reagent CytoPainter
(ab176753; Abcam, MA, USA) at 200 µl per well was used to
stain F-actin cytoskeleton (room temperature in the dark for
1–2 h) and washed again 2–3 times with PBS. Cell nuclei were
labeled with 200µl of 1:1,000 Hoechst stain (cat # 861405; Sigma-
Aldrich) for 5–10min. Cells were visualized using a SP5 laser
scanning confocal microscope (Leica, Germany).
Pathway Enrichment Analysis of Migratory
Genes Affected by CKI
RNA-seq (RNA-sequencing) data (23) of MDA-MB-231 cells
treated with CKI were used to identify cell migration genes
affected by CKI. Gene Ontology (GO) enrichment analyses
were carried out with R package clusterProfiler 3.8.0 (10). The
following parameters for GO enrichment analysis were used:
biological process at the third level; right-sided hypergeometric
test; and Benjamini-Hochberg method to correct p-values. P-
value cutoff 0.05 and FDR (false discovery rate) 0.1 values
were used to identify significantly over-represented GO terms.
Pathways that were significantly perturbed by CKI treatment
were identified with Signaling Pathway Impact Analysis (SPIA)
(27), and visualized using the pathview package in R (28).
KEGG (Kyoto Encyclopedia of Genes and Genomes) functional
analysis was performed with R package clusterProfiler 3.8.0
(10) and OmicCircos v 1.18.0 (29). Venn diagrams were
generated using an online tool (http://bioinformatics.psb.ugent.
be/webtools/Venn/).
Intracellular Protein Staining and
Quantification by Flow Cytometry
Cells cultured in 6-well trays were treated with CKI, MN or MJ
as described above, harvested after 24 h, fixed and permeabilized
using Nuclear Factor Fixation and Permeabilization Buffer
Set (Biolegend, CA, USA) according to the manufacturer’s
instructions. 2× 105 cells were labeled with rabbit anti-Cyclin D1
(CCND1) (92G2, Cell Signaling Technologies, MA USA), rabbit
anti-β-actin (ACTB) (D6A8, Cell Signaling Technologies), rabbit
anti-protein kinase B (AKT1, 2, 3) (Ab32505, Abcam) or rabbit
IgG isotype control (Cell Signaling Technologies), and these
antibodies were detected with anti-rabbit IgG-PE (Cell Signaling
Technologies). For detection of β-catenin, rabbit anti-β-catenin
(CTNNB1)-Alexa Fluor 647 and isotype control for CTNNB1
rabbit IgG-Alexa Fluor 647 (Abcam) were used. The cells were
then sorted, and the data were acquired on a BD LSRFortessa X-
20. Sorting parameters were set to gate and exclude small particles
such as cell debris and large duplex cells. The data were analyzed
using FlowJo software.
Statistical Tests
Statistical analyses were carried out using GraphPad Prism
8 software (San Diego, CA, USA) with one-way ANOVA.
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Statistically significant results were represented as ∗p < 0.05 or
∗∗p < 0.01; ∗∗∗p < 0.001 or ∗∗∗∗p < 0.0001; ns (not significant).
All data are shown as mean ± standard deviation (SD); n values
for independent samples are indicated in italics above the x-axes
in histogram figures, unless otherwise stated.
RESULTS
Functional Annotation of MDA-MB-231
Transcriptome Treated by CKI
Transcriptome (23) analyses were performed to identify over-
represented Gene Ontology (GO) terms and Kyoto Encyclopedia
of Genes and Genomes (KEGG) for all differentially expressed
(DE) genes by comparing MDA-MB-231 gene expression
profiles with and without CKI treatment (Figure 1 and
Supplementary Image 1). Differences in gene expression
levels were used to identify migration related GO terms and
pathways of interest, which were classified by functional
roles via GO and KEGG over-representation analyses.
Enriched GO terms connected to cell migration such as
“positive regulation of locomotion,” “tissue migration,” and
“leucocyte migration” emerged from analyses of DE genes
in CKI-treated MDA-MB-231 cells (Supplementary Image 1
and Supplementary Data Sheet 1). Integration of DE genes
associated with CKI treatment into KEGG pathways showed
that some of the most over-represented pathways were “focal
adhesion,” “regulation of actin cytoskeleton,” “pathways
in cancer,” “TGF-β signaling pathway,” and “adherens
junction” (Figure 1). These results indicated that many of
the genes affected by CKI treatment were involved in cell
migration-related pathways.
Identification of CKI Components
CKI was fractionated and components were selectively
recombined to create MJ and MN fractions
(Supplementary Image 2) as treatments for bioassays on
cultured cells. Concentrations of the nine major compounds
in CKI were measured using LC-MS/MS (see Materials
and Methods). The concentrations of MJ components were
determined (Supplementary Images 3, 4) from calibration
curves of nine standard compounds as previously described
(23) and summarized in Supplementary Table 1. The total
concentration of the nine major compounds in CKI was 9.99
mg/ml which accounted for approximately 40 % of the dry mass
of CKI, and the total concentration of the nine compounds in
FIGURE 1 | Summary of the KEGG analyses of over-represented pathways for differentially expressed genes after CKI treatment in MDA-MB-231 cells. From outer to
inner, the first circle indicates the pathways; the second shows the genes involved; and the third summarizes significant changes in expression for transcript levels that
were upregulated (red) or downregulated (blue) following CKI treatment. P-value cutoff for KEGG analysis was 0.05.
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MJ was 8.62 mg/ml, indicating that the major compounds were
clearly fractionated from CKI, and that MJ and MN components
were well-separated.
Impairment of Cell Migration by CKI and
Fractionated Mixtures
Effects of CKI on two-dimensional cell migration were assessed
using a circular wound healing assay (Figure 2A). Percent wound
closure after 20 h was calculated based on the initial wound
area. CKI-based treatments were tested on six different cancer
cell lines (HT-29, SW-480, DLD-1, U-87MG, U-251MG and
MDA-MB-231) and two non-cancerous cell lines (HEK-293 and
HFF), at five doses ranging from 0 to 2 mg/ml (Figure 2B). In
all cell lines, net migration rates were inhibited more by CKI
than by MN or MJ treatments alone, except in HEK-293 which
showed low sensitivity to CKI. The retention of biological activity
in the fractionated MJ and MN treatments was confirmed by
demonstrating reconstituted CKI (in which MN and MJ were
mixed together) was equally effective as CKI for blocking cell
migration (Figure 2B). The most sensitive cell lines were breast
cancer (MDA-MB-231) and colon cancer (HT-29). DLD-1 and
HEK-293 cell lines were the least sensitive.
In all the CKI-sensitive cell lines, the inhibition of migration
by MN alone was greater than that seen with MJ alone except
in HEK-293 and U-251 MG (Figure 2B), but neither treatment
was as potent as CKI in any cell line. To determine if a single
compound in MJ accounted for the enhanced inhibition seen
with co-application of MJ and MN, each of the isolated major
compounds alone was added in turn to 1 mg/ml MN, at a final
concentration equal to its original concentration in 2 mg/ml
CKI. Wound healing assays showed certain compounds added
to MN produced a significantly greater inhibition than MN
alone, but the effective compounds and levels of potency differed
between cell lines (Figure 2C and Supplementary Image 5).
Matrine was effective in MDA-MB-231, HT-29 and U-251MG
cell lines; sophocarpine was effective in HEK-293; trifolirhizin
was effective in HT-29, SW-480 and U-251MG; and adenine was
effective in HT-29 cells, as determined by a significant decrease in
migration as compared to MN alone. More than one compound
in MJ appeared to contribute to the activity of CKI in blocking
cell migration.
None of the CKI-based treatments induced significant
cytotoxicity at 1 or 2 mg/ml, as assessed by Alamar Blue assays
(Figures 3A–C). The lack of cytotoxicity suggested that the
observed impairment of the two-dimensional cell migration was
not an indirect consequence of reduced cell viability. However,
CKI at 2 mg/ml substantially increased apoptosis in MDA-MB-
231, without a significant effect on HEK-293 or HFF cell lines
(Figures 3D–G). These data extend prior work which showed
CKI increased apoptosis in MCF-7 breast cancer cells (17), and
support the idea that multiple responses induced by CKI could
contribute to its overall anti-cancer effects.
To quantify the effects of CKI on two-dimensional cell
motility in vitro in more detail, trajectories of individual cells
were monitored in real time using live cell imaging (Figure 4).
Vehicle-treated cells were compared with those treated with
2 mg/ml CKI, or 1 mg/ml MN or MJ (doses equal to their
concentration in CKI). Data were compiled for representative
cells from six cancer and two non-cancerous cell lines. Positions
of individual cells as a function of time over 20 h were determined
by the location of the cell nucleus (Figure 4A). Distances moved
per unit time interval showed a Gaussian distribution; the peak
position illustrates the mean distance traveled per increment.
Significant displacement of the curve to the left (representing
a decreased mean distance traveled per time interval) was
evident for CKI treatment in all cell lines as compared to
vehicle-treated controls (Figure 4B and Supplementary Video).
Significant reductions in mean distance by either MN or MJ
were observed in HT-29 and SW-480 cells. Reductions in mean
distance by MN but not MJ were seen in U-87MG, MDA-
MB-231 and HFF cells. U-251MG and DLD-1 cancer cells
responded only to whole CKI. The effectiveness of CKI in
blocking migration depended on the simultaneous presence of
multiple minor and major compounds, but the specific agents
conferring anti-migration activity appeared to depend on the
cell line.
Impairment of Invasiveness by CKI
Treatments in Cancer and Non-cancer
Cell Lines
A transwell Boyden chamber assay with ECM-coated filters
was used to measure the invasiveness of cells in response to a
serum chemoattractant gradient in vehicle control, CKI, MN,
and MJ treatment conditions (Figure 5). CKI treatment and
the combined MN+MJ treatment (i.e., reconstituted CKI) both
significantly reduced invasiveness in all cell types. Smaller but
significant decreases in invasiveness were seen with MN alone
in all cell types except SW-480 and were seen with MJ alone
in all but SW-480 and MDA-MB-231 cell lines. These results
suggested that a combination of major and minor components of
CKI was required for maximal inhibition of invasiveness through
extracellular matrix barriers.
Transcriptome Analysis of MDA-MB-231
Cells Treated With CKI
Functional enrichment analysis was used to narrow the field of
candidate mechanisms potentially associated with the effects of
CKI. The main finding was that the major pathways affected
by CKI treatment were cell migration-related. Perturbations of
KEGG Pathways that were significantly over-represented in DE
genes with CKI treatment were further analyzed using SPIA
(Figure 6A and Supplementary Data Sheet 2). “Melanogenesis,”
“TGF-β signaling pathway,” “focal adhesion,” “regulation of
actin cytoskeleton,” “ErbB signaling pathway,” and “GnRH
signaling pathway” were significantly perturbed based on “global
perturbation values” (pG < 0.05), consistent with the results
of the KEGG analysis. CKI appears to impair cell migration
by altering both adhesion and motility (Figures 6B,C). Genes
from two strongly affected pathways (“focal adhesion” and
“actin cytoskeleton”) were characterized by comparing three
independent gene datasets: (i) a set containing 135 Tumor
Alterations Relevant for Genomics driven Therapy (TARGET)
genes; (ii) a set containing 140 migration related genes collected
from published articles; and (iii) a set containing 1,381 genes
from KEGG pathways. We identified 14 clinically relevant
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FIGURE 2 | Dose-dependent inhibition of cell migration by CKI, MJ and MN fractions in eight cell lines, measured by wound closure assays. (A) Wound areas were
imaged at 0 h (initial) and after 20 h of treatment. (B) Graphs show percent inhibition of cell migration standardized to the initial wound area, as a function of dose for
treatments with CKI (blue), MJ (green), MN (red), and reconstituted CKI with major and minor fractions combined (MN+ MJ; purple). (C) Combinatorial analysis of
effects on wound closure for the MN fraction tested in combination with each of nine individual major compounds of CKI, summarized as a heatmap. Data were
normalized to values for percentage of migration blocked with MN alone at 0.5 mg/ml. Boxes display the net effects of added single major compounds, as no change
(white), increased percentage block (red), or reduced percentage of migration blocked (blue). Statistically significant differences are shown as *p < 0.05 and ***p <
0.001. No symbol in a box indicates the response was not significantly different from that with MN alone.
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FIGURE 3 | Assessment of the effects of CKI and fractions on cell viability and incidence of apoptosis. Viability was measured by Alamar Blue assay in eight cell lines
treated with (A) CKI, (B) MN or (C) MJ fractions (at doses present in 2 mg/ml CKI). Cell viability responses standardized as a percentage to mean values for vehicle
control were not significantly different (ns) in any condition, based on repeated experiments with 8 replicates total. Apoptosis was compared in three cell lines with and
without CKI treatment, for (D) MDA-MB-231, (E) HEK-293, and (F) HFF cells, analyzed by flow cytometry (see Methods for details). Pseudo-color plots illustrate the
percentages of cells in the late (quadrant Q2) and early (Q3) stages of apoptosis. (G) Histogram summarizing compiled data (mean ± SD) depicting percentage
apoptosis in three cell lines with and without CKI treatment. ****p < 0.0001; ns, not significant.
DE genes, which were: CTNNB1, CDH1, AKT1, AKT2, AKT3,
CCND1, MAPK1, JAK2, APC, CDK4, RB1, PIK3CA, and PTEN,
all of which have been shown to affect cell migration (Figure 6D,
Supplementary Table 3, and Supplementary Data Sheet 3),
suggesting that the slowing of cell migration could be clinically
relevant to CKI treatment outcomes.
CKI Interrupts F-actin Polymerization
The results of functional enrichment analysis highlighted the
actin cytoskeleton and focal adhesion pathways as potential
targets of CKI. As a result, we decided to examine the
effect of CKI on F-actin polymerization, filopodia formation
and lamellipodia extension using confocal microscopy in all
eight cell lines (Figure 7). Cells in all lines treated with
CKI, MN and MJ (at doses equal to those in 2 mg/ml
CKI) at 24 h were smaller and lacked cellular processes
such as lamellipodia as compared to vehicle control treated.
Abundant lamellipodia seen in the control treatment were
visibly diminished in the treatment groups. Comparing responses
within the treatment groups, CKI disrupted the lamellipodia
extensions more than was seen with MN or MJ alone. The
impairment of F-actin polymerization was consistent with
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FIGURE 4 | Live-cell imaging of individual cell migration trajectories, with and without the treatments in eight cell lines. Six representative cells located near wound
boundaries were selected at time zero and tracked by time-lapse imaging at 10-min intervals for 20 h by the positions of cell nuclei. (A) Trajectory plots of individual
cells, starting at the graph origin at time 0, were assigned in quadrants based on treatment groups: VC (vehicle control, blue), CKI (red), MN (green), and MJ (violet). X
and Y axis values are in µm. (B) Frequency histograms of distances moved by individual cells per 10-min interval over 20 h . Colors indicate treatment groups, as
above. Total cumulative distances moved per cell are collated in box plots (insets). Boxes enclose 50% of values; error bars show the full range; and horizontal lines
are median values. Statistically significant difference is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001, ****p < 0.0001; ns, not significant.
the idea that MN and MJ fractions both contribute slowing
cell migration.
CKI and Fractionated Mixtures Perturb the
Actin Cytoskeleton
To validate the gene expression changes at the protein level, we
performed flow cytometry analyses of four proteins; CTNNB1,
AKT (1–3), CCND1, and ACTB, selected for their significant
contributions in actin cytoskeleton and focal adhesion pathways
in MDA-MB-231, HEK-293, and HFF cell lines. Results shown
in Figure 8 indicated that CKI, MN and MJ significantly
downregulated the protein expression, confirming the gene
expression data. While there was prominent down-regulation
of CTNNB1, CCND1, and ACTB expression in MDA-MB-
231 by all treatments, AKT (1–3) was downregulated by CKI
and MN but not MJ treatments. In HFF cells, all treatments
downregulated ACTB and CCND1 significantly; CKI and MN
significantly reduced AKT (1–3) expression whereas MJ caused
significant increase. In contrast, in the HFF cell line, CTNNB1
protein expression was significantly increased by CKI and MN,
but significantly downregulated by MJ. In HEK-293 cells, CKI
upregulated ACTB, AKT and CCND1, whereas MN upregulated
ACTB and downregulated CTNNB1 with no significant effect
on AKT (1,2,3) or CCND1; MJ had no significant impact on
these four proteins (Figure 8). These results showed that CKI,
MN and MJ significantly downregulated the four proteins in
MDA-MB-231 cells, with similar although not identical results
in the two non-cancer cell lines, providing additional support
for the idea that CKI affects cancer cell migration by altering
cytoskeletal structure.
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FIGURE 5 | Effects of CKI and fractions on cell invasiveness in eight cell lines. Migration efficiencies of cells across an extracellular matrix barrier after treatment with
CKI, minor (MN), major (MJ), or combined (MN+MJ) fractions were measured by transwell invasion assays. (A) Images show stained cells that had passed through
the filter to reach the opposite side of the transwell membrane. CKI, MN and MJ were applied at doses equal to those present in 2 mg/ml CKI; Ctrl is vehicle control.
(B) Compiled results are shown in histograms; n-values are in italics in corresponding figure key. Statistically significant differences compared to vehicle control are
indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant.
DISCUSSION
Natural compounds with anti-cancer activities have been
suggested to include potential anti-metastatic agents (17, 21, 30,
31). Clinical chemotherapeutics for cancers are targeted mainly
at killing rapidly dividing cells (32), but cause serious side
effects including immunosuppression, hair loss and infertility,
without eliminating risks of secondary neoplasms (33). Non-
toxic treatments to reduce metastasis as adjuncts to primary
cancer therapies are greatly needed. CKI increased apoptotic
activity in breast cancer MCF-7 and hepatocellular carcinoma
HCC cell lines (17, 21). Results here showed that CKI also
significantly slowed cell migration and invasion, an outcome
consistent with its beneficial clinical effects. CKI is a mixture
of natural compounds containing nine major and numerous
unidentified minor compounds. The complexity of TCM
presents a challenge for identifying single active compounds. By
separating components of CKI into major and minor groups,
and by adding novel screens for migration and invasion into
the analyses of CKI biological activity, we have shown that
co-application of multiple compounds was far more effective
in blocking cell migration than single agents alone, and that
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FIGURE 6 | Identification of significantly perturbed pathways using SPIA analysis. (A) 101 significantly perturbed pathways in MDA-MB-231 treated by CKI 2 mg/ml
were observed. Total perturbation values are shown on the x-axis, and pathway IDs are on the y-axis. The global perturbation P-value (pG < 0.05) was used. (B)
Significantly perturbed “focal adhesion” pathway in MDA-MB-231 treated by CKI 2 mg/ml. (C) Significantly perturbed “regulation of actin cytoskeleton” pathway in
MDA-MB-231 treated by CKI 2 mg/ml. Up- and down-regulated genes are shown in red and green, respectively and genes that were not affected by CKI treatment
are shown in white or gray. (D) 14 “core genes” that are found across three different datasets (see Methods).
different compounds (serendipitously combined in CKI) are
required for activity across diverse cell types. We showed the
inhibition of migration by the major fraction alone was not as
potent as whole CKI in any of the cell lines tested, demonstrating
one or more minor compounds were necessary for the full
effect. Each of the single compounds in the major fraction
was coapplied with the minor fraction to test for a dominant
modulator, but interestingly the most effective combinations
of compounds differed between cell lines (Figure 2C and
Supplementary Image 5). More than one major compound
contributes to the activity of CKI in blocking cell migration.
Components of CKI have both anti-proliferation and
anti-migration activities which differ between cell lines,
suggesting that refinement of the TCM composition could
enable customized management for different cancer types. A
subset of the major compounds in CKI have been investigated
previously. For example, oxymatrine impaired angiogenesis in
mouse breast cancer in vitro and in vivo, by altering NF-κB
pathway and VEGF signaling (34). Matrine inhibited migration
and proliferation of mouse lung adenocarcinoma in vitro and
slowed xenograft growth in vivo, by reducing expression of a
calcium-dependent chloride channel shown to be upregulated
in multiple cancer types (35, 36). Consistent with these findings,
we found matrine added to the CKI minor fraction further
impaired cancer cell migration (Figure 2C); however, in
contrast, addition of oxymatrine to the CKI minor fraction did
not affect the control of migration in any of the cell lines we
tested. Oxysophocarpine slowed metastasis of oral squamous cell
carcinoma in vitro and in vivo, by altering transcription factor
Nrf2 and stress protein signaling pathways (37). In contrast,
our results showed oxysophocarpine partially reversed the
inhibition of migration observed with the CKI minor fraction.
Work here showed that the major components trifolirhizin
and adenine, not previously characterized, when added to CKI
minor fraction further slowed cell migration, suggesting these
agents merit further study as potential therapeutics, singly
and in combination. Not all components of CKI enhance its
anti-cancer activities; for example, depletion of three compounds
(oxymatrine, oxysophocarpine and macrozamin) increased the
anti-proliferative activity of CKI (23).
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FIGURE 7 | Patterns of distribution of polymerized F-actin after CKI-based treatments in eight cell lines, visualized by confocal microscopy. (A) F-actin was labeled
with phalloidin (green), and nuclei with Hoechst (blue), for treatment groups (from left to right): vehicle control (Ctrl), CKI, minor and major fractions at doses present in
2 mg/ml CKI. Scale bars are 50µm. (B) Areas (µm2 ) of F-actin staining per cell are summarized in box plots. Statistically significant results are shown as *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 and (ns) for not significant.
Rational analysis of the differential effects of agents in a
TCM mixture can benefit from quantitative systems biology
approaches. Transcriptomics has proven valuable for identifying
altered patterns of global gene expression in response to
complex agents such as CKI (18). Our pathway analysis of
the transcriptome of CKI-treated MDA-MB-231 cells revealed
a strong association with genes linked to “TGF-β signaling,”
“focal adhesion,” “GnRH signaling,” and “regulation of actin
cytoskeleton.” These pathways are linked with migratory
phenotype, actin polymerization and lamellipodia protrusion
(38–40). Focal adhesion sites are points of contact with
extracellular matrix, anchoring actin filaments via protein
complexes with transmembrane integrin receptors (41). Matrine
has been reported to disrupt actin filament organization in
DLD-1 colorectal adenocarcinoma cells (42). Work here is
the first to show that treatment with whole CKI significantly
perturbed “focal adhesion” and “regulation of actin cytoskeleton”
pathways, and to confirm predictions of the transcriptomic
results by showing CKI reduced lamellipodial abundance, length
of extension, and area of F-actin polymerization.
Two striking outcomes of our pathway analyses were
the significant negative perturbation of the cytokine TGF-β
(transforming growth factor beta) and positive perturbation of
GnRH (Gonadotropin-releasing hormone) signaling pathways
by CKI treatment. Multifunctional TGF-β promotes the process
of epithelial-mesenchymal transition, which facilitates cell
migration, invasion and metastasis (43, 44). Reduced TGF-β
signaling would be consistent with our findings of impaired
invasion and migration with CKI treatment. Conversely, GnRH
activity has been associated with attenuating migration of
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FIGURE 8 | Flow cytometry analyses of four proteins: CTNNB1, AKT (1–3), CCND1, and ACTB compared in three cell lines with and without CKI-based treatments.
The levels of protein expression for four genes predicted by transcriptomic analysis to be significantly down-regulated were evaluated by FACS in three cell lines (A)
MDA-MB-231, (B) HEK-293, and (C) HFF. Statistically significant differences compared to vehicle controls were analyzed using one-way ANOVA and post hoc tests
and are shown as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and not significant (ns).
DU145 human prostatic carcinoma cells by remodeling the
actin cytoskeleton (45). Increased GnRH signaling would be
consistent with beneficial effects of CKI treatment. Further work
is needed to fully understand the mechanisms of action of CKI
on cell migration and invasion, the signaling pathways involved,
the synergistic effects of combined therapeutic agents, and the
translational potential by extending these analyses to metastatic
cancer cells in vivo. Our results showed not only that more
than one component of CKI is necessary for a beneficial effect
in slowing migration, but that the optimal combinations of
coapplied agents are not universal across all types of cancers.
This work suggests future opportunities exist to refine CKI
composition to target different classes of cancers differentially.
CONCLUSION
The primary outcome of this study is the demonstration that
cancer cell migration and invasion rates are significantly reduced
by CKI, suggesting that therapeutic activity of CKI in human
cancer patients may arise in part from downregulation of a panel
of key molecular targets necessary for adhesion and motility in
metastasis. The secondary outcome of this study is that multiple
compounds in CKI, acting together, are responsible for this effect.
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Supplementary Image 1 | Functional classification of genes by GO
over-representation analyses. Over-represented GO terms (Biological Process,
BP = 3) for differentially expressed (DE) genes were identified from MDA-MB-231
cells treated by CKI. Upregulated and downregulated genes contained in each
term were shown in red and green, respectively. GO terms shown above the blue
line were significant terms related to migration.
Supplementary Image 2 | HPLC profiles of the components present in (A) CKI,
(B) MJ, and (C) MN fractions. Samples (50 µl at 1 mg/ml) were run through a C18
semi-preparative column. Numbers indicate the nine major compounds; 1:
macrozamin, 2: adenine, 3: n-methylcytisine, 4: sophoridine, 5: matrine, 6:
sophocarpine, 7: oxysophocarpine, 8: oxymatrine, and 9: trifolirhizin.
Supplementary Image 3 | (A) Total ion chromatogram (TIC) for CKI in 1 in 100
dilution from 25 mg/ml of stock concentration. Single peaks were extracted based
on the molecular mass. (B) cytisine (spike in control), (C) macrozamin,
(D) adenine, (E) n-methylcytisine, (F) sophoridine and matrine (similar molecular
mass with different retention time) (G) oxysophocarpine, (H) oxymatrine, (I)
sophocarpine, and (J) trifolirhizin.
Supplementary Image 4 | (A) Total ion chromatogram (TIC) for MJ in 1 in 100
dilution from 25 mg/ml of stock concentration. Single peaks were extracted based
on the molecular mass. (B) adenine, (C) cytisine (spike in control), (D)
macrozamin, (E) n-methylcytisine, (F) sophoridine, and matrine (similar molecular
mass with different retention time) (G) oxysophocarpine, (H) oxymatrine, (I)
sophocarpine, and (J) trifolirhizin.
Supplementary Image 5 | Combinatorial analysis of the effects of MN with each
of the nine major individual compounds, analyzed in eight cell lines with wound
closure assays. Data were normalized to results with 0.5 mg/ml minor (MN) alone.
Significantly increased or decreased percent block of migration resulting from the
addition of major compounds is shown as ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,
and not significant (ns). Data are mean ± SD.
Supplementary Video | Live-cell imaging of the migration blocking effect of CKI
in MDA-MB-231 cells in the wound closure migration assay. Videos show cell
motility and wound closure rate in CKI at 2 mg/ml was reduced as compared to
untreated control. Images were captured at 10-min intervals for 20 h.
Supplementary Data Sheet 1 | Significantly over-represented functional GO
terms, as determined by GO analysis of the transcriptome from CKI treated
MDA-MB-231 cells (P < 0.05).
Supplementary Data Sheet 2 | Significantly perturbed pathways, as determined
by SPIA analysis of the transcriptome from CKI treated MDA-MB-231 cells.
(pG < 0.05).
Supplementary Data Sheet 3 | Matching of genes in two strongly affected
pathways (“focal adhesion” and “actin cytoskeleton”) against three independent
gene datasets containing: (i) a set TARGET gene and (ii) migration related genes
from published articles. 14 core DE genes from three datasets including CTNNB1,
CDH1, AKT1, AKT2, AKT3, CCND1, MAPK1, JAK2, APC, CDK4, RB1, PIK3CA,
and PTEN, are known to have effects on cell migration.
Supplementary Table 1 | Concentration of 9 major compounds in CKI (Batch
No:20151139) and MJ. Total alkaloid content in CKI (Batch No:20151139) = 25
mg/ml based on manufacturer’s assay. Regression line for the calculation of
compounds has previously been described (23).
Supplementary Table 2 | Concentrations of Matrigel and number of cells used
for each cell line in transwell invasion assay.
Supplementary Table 3 | Fourteen clinically relevant DE genes from three
independent gene datasets.
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